References
- Streetly A, Latinovic R, Hall K, Henthorn J. Implementation of universal newborn bloodspot screening for sickle cell disease and other clinically significant haemaglobinopathies in England: Screening results for 2005–2007. J Clin Pathol. 2009;62(1):26–30
- Halasa NB, Shankar SM, Talbot TR, et al. Incidence of invasive pneumococcal disease among individuals with sickle cell disease before and after the introduction of the pneumococcal conjugate vaccine. Clin Infect Dis. 2007;44(11):1428–1433
- Ellison AM, Ota KV, McGowan KL, et al. Pneumococcal bacteremia in a vaccinated pediatric sickle cell disease population. Pediatr Infect Dis J. 2012;3(5):534–536
- Baskin M, Goh XL, Heeney M, et al. Bacteremia risk and outpatient management of febrile patients with sickle cell disease. J Pediatr. 2013;131(6):1035–1041
- Narang S, Fernadnez ID, Chin N, et al. Bacteremia in children with sickle hemoglobinopathies. J Pediatr Haematol Oncol. 2012;34(1):13–16
- Rogovik AL, Friedman JN, Persaud J, Goldman RD. Bacterial blood cultures in children with sickle cell disease. Am J Emerg Med. 2010;28(4):511–514
- Kizito M, Mworozi E, Ndugwa C, et al. Bacteraemia in homozygous sickle cell disease in Africa: Is pneumococcal prophylaxis justified? Arch Dis Child. 2007;92(1):21–23
- Bansil N, Kim T, Tieu L, Barcega B. Incidence of serious bacterial infections in febrile children with sickle cell disease. Clin Pediatr. 2013;52(7):661–666
- Wilimas JA, Flynn P, Harris S, et al. A randomized trial of outpatient treatment with Ceftriaxone for selected febrile children with sickle cell disease. New Eng J Med. 1993;329(7):472–476
- Rogers ZR, Morrison RA, Vedro DA, Buchanan G. Outpatient management of febrile illness in infants and young children with sickle cell anemia. J Pediatr. 1990;117(5):736–739
- Williams LL, Wilimas JA, Harris SC, et al. Outpatient therapy with Ceftriaxone and oral Cefixime for selected febrile children with sickle cell disease. J Pediatr Haematol Oncol. 1996;18(3):257–261
- Aljuburi G, Laverty AA, Green SA, et al. Trends in hospital admissions for sickle cell disease in England. 2001/02-2009/10. J Public Health (Oxf). 2012;34(4):570–576 doi: 10.1093/pubmed/fds035
- Pizzo E, Laverty AA, Phekoo KJ, et al. A retrospective analysis of the cost of hospitalizations for sickle cell disease with crisis in England, 2010/11. J Public Health (Oxf). 2014 May 5. doi: 10.1093/pubmed/fdu026
- Dale JC, Cochran CJ, Roy L, et al. Health-related quality of life in children and adolescents with sickle cell disease. J Pediatr Health Care. 2011;25(4):208–215
- West D, Andrada E, Azari R, et al. Predictors of bacteremia in febrile children with sickle cell disease. J Pediatr Hematol Oncol. 2002;24(4):279–283
- Mohammed FA, Mahdi N, Sater MA, et al. The relation of C-reactive protein to vasoocclusive crisis in children with sickle cell disease. Blood Cells Mol Dis. 2010;45(4):293–296
- National Heart, Lung, and Blood Institute. Division of Blood Diseases and Resources. The Management of Sickle Cell Disease, 4th ed. Bethesda, MD: National Institute of Health; 2002. (https://www.nhlbi.nih.gov/files/docs/guidelines/sc_mngt.pdf)
- Norris C, Smith-Whitely K, McGowan K. Positive blood cultures in sickle cell disease: Time to positivity and clinical outcome. J Pediatr Hematol Oncol. 2003;25(5):390–395